Lexeo Therapeutics, Inc. LXEO R2KR3KPHARMA
Company Overview
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +3.60% |
| 6 Months: | -28.61% |
| 3 Months: | +11.90% |
| 1 Month: | +7.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)51.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 54.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LXEO Lexeo Therapeutics, Inc. R2KR3KPHARMA | 4.89 | -4.37 | $383.97M | 0.00% | -43.38% | -54.75% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 531.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | -17.48M | -19.29M | -13.97M | -20.27M | -23.29M | -23.55M | -31.54M | -33.80M | -30.69M | -21.65M | -22.33M |
| Net Income | -12.50M | -15.14M | -17.05M | -18.66M | -13.44M | -20.11M | -21.68M | -21.24M | -29.49M | -32.66M | -26.10M | -20.28M | -20.20M |
| Diluted EPS | - | - | -10.38 | -11.58 | -8.30 | -12.36 | -0.77 | -0.64 | -0.89 | -0.99 | -0.60 | -0.33 | -0.25 |
| R&D Expense | - | - | 15.36M | 16.44M | 11.24M | 17.25M | 15.74M | 16.56M | 23.42M | 17.17M | 14.72M | 15.70M | 15.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 654.00K | - | - | - |
| Operating Income | -60.51M | -68.51M | -105.77M | -109.26M |
| Net Income | -59.28M | -66.39M | -98.33M | -99.96M |
| Diluted EPS | -36.36 | -12.40 | -3.09 | -1.86 |
| R&D Expense | 49.16M | 53.13M | 74.09M | 63.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 97.08M | 139.81M | 146.94M | 268.69M |
| Current Assets | - | 80.05M | 124.29M | 126.12M | 188.39M |
| Cash & Equivalents | - | 77.33M | 121.47M | 35.01M | 63.00M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Total Liabilities | - | 210.03M | 26.27M | 30.10M | 22.02M |
| Current Liabilities | - | 14.35M | 17.24M | 22.85M | 16.81M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 13.48M | 11.64M | 9.92M | 7.89M |
| Total Equity | - | -112.95M | 113.53M | 116.84M | 246.67M |
| Shares Outstanding | - | 25.17M | 26.67M | 33.08M | 73.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -54.56M | -59.50M | -81.15M | -98.56M |
| Investing Cash Flow | -901.00K | -165.00K | -94.08M | -90.25M |
| Financing Cash Flow | 189.00K | 103.79M | 88.78M | 216.79M |
| Capital Expenditure | -672.00K | -115.00K | -481.00K | -397.00K |
| Free Cash Flow | -55.23M | -59.61M | -81.63M | -98.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -9,252.1% | - | - | - |
| Net Margin % | -9,063.8% | - | - | - |
| ROE % | 52.5% | -58.5% | -84.2% | -40.5% |
| ROCE % | -73.1% | -55.9% | -85.2% | -43.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Montanova Capital LLC | 7.78% | 6.38M | $31.03M |
| 2 | Affinity Asset Advisors, Llc | 7.08% | 5.81M | $28.22M |
| 3 | Blackrock Inc. | 7.00% | 5.74M | $27.89M |
| 4 | RA Capital Management, L.P. | 6.09% | 5.00M | $24.30M |
| 5 | Frazier Life Sciences Management, L.P. | 5.88% | 4.82M | $23.45M |
| 6 | State Street Corporation | 5.31% | 4.35M | $21.16M |
| 7 | Vestal Point Capital, LP | 5.27% | 4.32M | $21.00M |
| 8 | Paradigm Biocapital Advisors LP | 5.09% | 4.18M | $20.29M |
| 9 | Jupiter Topco LLC | 4.82% | 3.95M | $19.22M |
| 10 | Orbimed Advisors LLC. | 4.81% | 3.95M | $19.19M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LXEO
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPak5QNjVRSTJSYjVUQ3lEemRUb04xRHZkZy16OHhJSlc5UDNUOTFKQnJiYkVibjBkTzhGaHZobnlhYWQ0clpHV2FIc2xNcWo3ekJGSTJjTUtKbUhfSm43aG9QMTd6S3RCX2tkUU1Qb3JmTmFzSExoMjRtZ2FWR2xtQkRfYjd1d25lNTdudG…
Insider Sale: Chief Financial Officer of $LXEO Sells 4,641 Shares | LXEO Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxORlVvenBWdElfaDRuNHg5M1dNSVF2OWx6dml6WDUxMWNjUmQzQ09qSV9vOVZpZ1FYRFNNcU5xdkR3Nkd3WmdJSkJKWUl6LTVUNjVmTnpoUlJWZmJTNjNmaFNxZWthamtzVFZZcm1XalI3Q2xWN1dqQUpOMjdDN2hYVDg3Y1ZOdVF2eXZwb3…
Lexeo Therapeutics (NASDAQ: LXEO) insider to sell 4,117 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOVU1TeTJKX3NNYTNMbXBHN185SllLMlg4SXo1VDdCcGFZd3VhRXphRGMwQ0dPOTNJVkxwNFZBY3otTTdybzd0aUdVcEV0RVRNSUxDYnpZQ3JvMk9Kc2htVzkwMHlNNXBaU0E1UlZOZzRnWm9EbWpTNngtblB1THBHNHE0OUd2MHlERG9JRk…
LXEO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1iQUpRbnA2dHpRSm4yOXBMRTdYU2FvVXQ1WG5QQ0k1MTBoNlE2cFRKd21uTHZfN3JIQ1c4RTd0UDRobjZaaVc4VWl0N3AtTnBFRWkxZktVQ0JSTktjOHZKZ1dJNThFcjliQm9ILS10ekZ3U19UM1QyanZ3?oc=5" target="_blank">LXE…
Here's Why We're Watching Lexeo Therapeutics' (NASDAQ:LXEO) Cash Burn Situation - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPbnFVVjFvOTItd2V4TjAyTnNuUzhoZVNtMEsxNmxNNG5iUTlRLWNQUUs2dm1qM1FkLV82V2V5LVRXRFRHa0FnQ2pyNm5KbEZhdjMyYV9ZcmlGNnJMZTVaa1FKLU5hcGVaT2tMMl9zQzZvOW5nMzdzY2VsWV9mZ1BuT0V4UWt1cmRKU0Q2V1…
(LXEO) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNU0tLeThCTUwzSkZKWnJlUTk3RVh5N2lkUHlpT2tfejVEU2duNFNkaExvTlBTT0phdjhlaDFZRk5GRnkxbG85RUc2Ym1JOF9LcjhYTXlMUlJhR2F3cENlQ1ktM2JwWk5xYVZ2bEVYc0tWSGpJWDhfQ0tzczFLdkdFWFFycF84c0p4YlpZeH…
LXEO — Frequently Asked Questions
What is the current share price of Lexeo Therapeutics, Inc. (LXEO)?
As of 2026-09-07 16:24 PDT, Lexeo Therapeutics, Inc. (LXEO) trades at $4.89 on NasdaqGM. Its 52-week range is $4.13 to $10.63.
What is the market capitalisation of LXEO?
Lexeo Therapeutics, Inc. (LXEO) has a market capitalisation of $383.97M on NasdaqGM.
What is the P/E ratio of LXEO?
LXEO trades at a trailing price-to-earnings (P/E) ratio of -4.37. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.54.
What is the return on equity (ROE) of LXEO?
LXEO has a return on equity (ROE) of -54.75%. Its return on capital employed (ROCE) is -43.38%.
Is LXEO a good stock to buy?
This page provides a data-driven analysis of Lexeo Therapeutics, Inc. (LXEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.